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Towards an optimal therapy strategy for
myogenous TMD, physiotherapy compared
with occlusal splint therapy in an RCT with
therapy-and-patient-specific treatment
durations
Robert J. van Grootel1, Rob Buchner2, Daniël Wismeijer3 and Hilbert W. van der Glas4,5*
Abstract
Background: Temporomandibular Disorders (TMD) may be characterized by pain and restricted jaw movements. In the
absence of somatic factors in the temporomandibular joint, mainly myogenous, psychobiological, and psychosocial
factors may be involved in the aetiology of myogenous TMD. An occlusal appliance (splint) is commonly used as a basic
therapy of the dental practice. Alternatively, a type of physiotherapy which includes, apart from massage of sore
muscles, aspects of cognitive-behavioural therapy might be a basic therapy for myogenous TMD. Treatment
outcome of physiotherapy (Ph-Tx) was evaluated in comparison to that of splint therapy (Sp-Tx), using the index
Treatment Duration Control (TDC) that enabled a randomized controlled trial with, comparable to clinical care,
therapy-and-patient-specific treatment durations.
Methods: Seventy-two patients were randomly assigned to either Ph-Tx or Sp-Tx, with an intended treatment
duration between 10 and 21 or 12 and 30 weeks respectively. Using TDC, the clinician controlled treatment
duration and the number of visits needed. A blinded assessor recorded anamnestic and clinical data to determine
TDC-values following treatment and a 1-year follow-up, yielding success rate (SR) and effectiveness (mean TDC)
as treatment outcomes. Cohen’s d, was determined for pain intensity. Overall SR for stepped-care was assessed in
a theoretical model, i.e. a second of the two studied therapies was applied if the first treatment was unsuccessful,
and the effect of therapy sequence and difference in success rates was examined.
Results: SR and effectiveness were similar for Ph-Tx and Sp-Tx (long-term SR: 51–60%; TDC: −0.512– −0.575).
Cohen’s d was 0.86 (Ph-Tx) and 1.39 (Sp-Tx). Treatment duration was shorter for Ph-Tx (on average 10.4 weeks
less; p < 0.001). Sp-Tx needed 7.1 less visits (p < 0.001).
Conclusions: Physiotherapy may be preferred as initial therapy over occlusal splint therapy in stepped-care of
myogenous TMD. With a similar SR and effectiveness, physiotherapy has a shorter duration. Thus patients whose
initial physiotherapy is unsuccessful can continue earlier with subsequent treatment. The stepped-care model
reinforces the conclusion on therapy preference as the overall SR hardly depends on therapy sequence.
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Background
Temporomandibular Disorders (TMD) is a collective term
embracing a number of clinical problems including condi-
tions of the masticatory musculature, the temporoman-
dibular joint and associated structures, or both [1]. These
disorders are characterized by pain and restricted jaw
movements. Inter-therapy outcome was studied for a basic
type of TMD. To that end, patients were selected who have
muscle disorders alone, corresponding to the myofascial
subtype according to the Research Diagnostic Criteria,
RDC/TMD [2], further denoted as myogenous TMD.
In the absence of somatic factors in the temporoman-
dibular joint, mainly myogenous, psychobiological, and
psychosocial factors may be involved in the aetiology of
myogenous TMD [3, 4]. Regarding myogenous factors, ex-
ternal events, for example, trauma, may initiate peripheral
sensitization of nociceptors in the masticatory muscles [5].
Psychobiological factors include those related to central
sensitization and dysfunctional descending pain modu-
lation [3, 5, 6]. Psychosocial factors related to stress,
emotion and somatic awareness interact with psycho-
biological factors [3, 4].
Therapy with an occlusal appliance (splint) is com-
monly used as a basic TMD treatment in the dental
practice [7]. An occlusal splint will alter afferent activity
from intra-oral tissues by covering teeth and providing
pressure on intra-oral tissues. Furthermore, an occlusal
splint alters the position of the temporomandibular joint
by increasing the vertical dimension of the mouth. In
motor control, a splint changes activity patterns of the
jaw closing muscles during clenching [8, 9]. As splint
therapy is not specific, the mechanisms underlying its
effectiveness are not well understood [10, 11]. In view of
aetiology, a type of physiotherapy which includes, apart
from massage of sore muscles, aspects of cognitive-
behavioural therapy, might be a basic therapy for myo-
genous TMD rather than splint therapy. Regarding other
features, the extent of a patient’s active participation is
larger for physiotherapy. Furthermore, patients whose
physiotherapy is ended successfully have learned tech-
niques to avoid stress and to relieve pain, which can be
used if they feel a need afterwards. Such techniques may
avoid the need of using an intra-oral appliance in the
long-term. It is therefore of interest to compare treat-
ment outcome of physiotherapy to that of splint therapy.
The effectiveness of occlusal splint therapy has previ-
ously been compared with other therapies or conditions
using traditional Randomized Controlled Trials (RCTs),
with a constant period of treatment of 6 weeks to
3 months [12–18]. In clinical care, however, the duration
of treatment varies as it depends on the type of therapy
as well as on a patient’s speed of recovery. When therap-
ies of TMD differ in mean duration, a constant period of
evaluation might influence an assessment of success rate
and effectiveness. A short period will favour short ther-
apies whereas a long period might be disadvantageous
by including post-treatment changes in the outcome.
For example, when a therapy with a mean duration of
2 months, is arbitrarily ended after 1 month for evalu-
ation, it will be unsuccessful in those patients who re-
spond so slowly that a residual level of signs and
symptoms of TMD is not reached after 1 month. Part of
these patients will attain a residual level with a longer
treatment. Hence, the percentage of successful treatments
across the entire patient sample of a therapy (success rate)
will be biased towards a smaller value when therapy evalu-
ation is carried out before treatments have been com-
pleted. An early evaluation also yields a smaller
improvement in an outcome variable, for example pain in-
tensity, of slowly responding patients. Hence, therapy ef-
fectiveness which is related to the degree of improvement
averaged across the entire patient sample, will then be
biased towards a smaller value. When two therapies, A
and B, are both arbitrarily evaluated after a relatively long
period, for example 3 months, while the mean duration of
these therapies is 1 and 2 months respectively, the therapy
outcome might be confounded by spontaneous changes in
signs or symptoms that are unrelated to these therapies,
between month 1 and 3 (therapy A) and between month 2
and 3 (therapy B). If a spontaneous change occurred in
the same direction for both therapies (a continuous in-
crease or decrease respectively), this change may be larger
for therapy A with a post-treatment interval of 2 months
than for therapy B with an interval of 1 month. If chance
fluctuations were involved, the incidence of these may
depend on the duration of the post-treatment interval and
thus differ between therapies A and B. One might argue
that chance fluctuations will be diminished by aver-
aging across a patient sample. However, this diminution
will be imperfect because patient samples have a
limited size. Hence, spontaneous changes may cause
artifactual differences between therapies in success rate
or effectiveness when unequal post-treatment intervals
are involved.
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Thus allowing a therapy-and-patient-specific vari-
ation of treatment duration in RCTs will comply with
clinical care, and enables an unbiased comparison of
the therapeutic potential of different therapies. Such a
type of RCT can be applied straightforwardly to non-
life threatening disorders like TMD. In contrast to an
RCT with variable treatment duration, a traditional
RCT does further not provide information on the ther-
apy duration and number of visits needed in individual
patients. This information is of interest for a complete
costs-effectiveness-analysis, and for attaining an opti-
mal therapy strategy for myogenous TMD as outlined
below.
The first aim of the present study was to evaluate treat-
ment outcome of physiotherapy in comparison to that of
splint therapy of myogenous TMD, using the index ‘Treat-
ment Duration Control’ (TDC) for enabling an RCT with a
therapy-and-patient-dependent number of visits and treat-
ment duration [19]. All three features of treatment outcome
have been addressed, i.e. (1) the time and number of visits
needed to decide whether a patient’s treatment is either
successful or unsuccessful, (2) success rate, and (3) therapy
effectiveness (cf. Methods).
Whereas a multi-therapy modality is most appropri-
ate for patients having TMD as well as major psycho-
logical problems, a single form of treatment each time
is indicated for most TMD categories [20]. A single
treatment modality could be applied, i.e. either physio-
therapy or splint therapy, as patients with mainly basic
signs and symptoms of myogenous TMD were selected
(cf. Methods). However, like in common clinical care,
an initial treatment became unsuccessful in a substan-
tial fraction of the patients (cf. Results). Because myo-
genous TMD is a non-life threatening disorder, a
trajectory of stepped-care is possible to increase the
overall success rate. A trajectory starts with a first type
of therapy which, if not successful, is followed by a sec-
ond type. Patients whose physiotherapy was unsuccess-
ful in the present study continued with splint therapy
and reversely. The overall success rate of a trajectory
may depend on (i) the therapies’ success rate when
applied separately, (ii) their sequence of successive ap-
plication, and (iii) a possible effect on the success rate
of a subsequent therapy by the preceding one. The
influence of these factors has been examined by using a
theoretical stepped-care model.
The second aim of the study was to examine
whether physiotherapy or splint therapy may be pre-
ferred as an initial treatment in stepped-care. To that
end, all features of therapy outcome were considered
as well as outcomes of the stepped-care model. A
preliminary report has been published previously, in
which patient samples and the validation of TDC
were not completed yet [21].
Methods
Patients
The study was carried out in compliance with the
Helsinki Declaration, and approved by the University
Ethics Committee and the Board of Developmental
Medicine in the Netherlands (reference: OG/93/002).
The myogenous TMD patients were either referred to
the Department in Utrecht (85%) or recruited directly
from general dental and medical practitioners (15%).
Recruitment, interventions and follow-ups occurred
between April 1993 and March 2000.
Out of 2078 patients, 187 patients (9%) were selected
who had solely myogenous TMD, using stringent cri-
teria. From these eligible patients, 37 patients (20%; nine
males and 28 females) declined participation, mainly be-
cause of time and distance reasons. The remaining 150
patients gave informed consent of which 60 patients
who had pronounced occlusal interferences participated
in an RCT with other interventions (see below), and 90
patients without pronounced occlusal interferences en-
rolled in the present study. The current procedures were
completed by 72 out of 90 patients, 37 patients for
physiotherapy and 35 ones for splint therapy. Hence, 18
out of 90 patients (20%) became dropouts (ten patients
for physiotherapy and eight patients for splint therapy,
Fig. 1) at various stages of the procedure, for the follow-
ing reasons: (1) the threshold of signs and symptoms
was not met at the start of treatment (one patient
assigned to physiotherapy), (2) problems with complying
to appointments (work situation, distance), and (3) not
able to complete treatment according to the protocol
(medical co-intervention, co-morbidity, acute dramatic
life events).
Assuming a mean baseline level of pain intensity of
30.6 mm on a 100 mm VAS for TMD [22], an SD of
19.0, and a reduction of the mean level of 35%, yielded
an estimated sample size of 50 patients in each group to
achieve a power of 0.80 at a level of type I errors of 5%.
Considering the number of complying patients, the
power has been calculated post-hoc for two types of out-
come variables (cf. Results and Additional file 1, ‘Post-
hoc power analysis on measures of effectiveness’).
As outlined in our previous study on pain patterns
from the same patients [23], RDC/TMD [2] was
followed to select group Ia and Ib patients (myofascial
pain) while excluding group II (disk displacement of the
Temporomandibular joint) and group III (arthralgia,
arthritis, arthrosis). Patients with mainly basic signs and
symptoms of myogenous TMD were selected, i.e. pa-
tients without possibly confounding influences from the
temporomandibular joint, dental anomalies, major
psycho-social factors, or factors affecting general health
[23]. A specific exclusion criterion was previous treat-
ment with an occlusal splint, occlusal adjustment, or
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physiotherapy of the masticatory system. Patients who
had other treatments for pain (also orofacial pain) more
recent than a year, were also excluded. Regarding major
psycho-social factors, patients with a recent dramatic life
event (details, see ref [23]) and/or psychotherapy and/or
use of psycho-medication, were excluded to avoid a pos-
sible influence of extremely large levels and fluctuations
of stress and/or an influence of types of medication,
which might overshadow the treatment effect of physio-
therapy or splint therapy. Hence, while stress which is
related to common daily activities was still possible, the
effect of physiotherapy or splint therapy on myogenous
TMD may then be more related to myogenous and psy-
chobiological factors. Table 1 shows pre-treatment
values of demographic and clinical variables. The pre-
treatment values of psychosocial variables, including
those related to anxiety, depression, health locus of con-
trol and coping style have been reported previously [23].
The aetiologic significance of occlusal interferences in
the dentition has been questioned because of weak asso-
ciations between such interferences and TMD in general
[24]. However, apart from critical considerations on the
dental literature about the relationship of occlusion and
myogenous orofacial pain, some well controlled clinical
and experimental studies are in favour of a possible
aetiologic role of occlusal interferences in myogenous
TMD [25]. Patients with pronounced occlusal interfer-
ences were therefore excluded in the present study for
diminishing the influence of a possibly confounding fac-
tor, using as exclusion criteria: (1) a forward sliding of at
least 2 mm and/or lateral sliding of at least 1 mm with
respect to centric occlusion; and (2) an interference on
the non-active side that is not accompanied with contact
on the active side.
Procedures between intake and start of treatment
At the initial visit, eligible patients were informed about
a study on treatment effect. The project funded travel
costs, costs of treatment if needed, and costs of, for
example, baby-sitting for follow-up visits. All partici-
pants were informed in a standardized way about TMD
as being a non-life threatening disorder with a lack of an
Fig. 1 Patient flow. Tx, treatment. FU, follow-up evaluation, 6 and 12 months after end of Tx. Dropout patients, patients who did not complete the
entire treatment procedure at various stages, for various reasons (see text); STx and UTx patients, patients whose Tx is successful or unsuccessful
respectively, according to the TDC procedure, at a particular stage; n-Ph Tx, number of patients assigned to physiotherapy; n-Sp Tx, number of patients
assigned to splint therapy
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unambiguous cause of the pain and about possible con-
tributing factors. The patients received counselling on
avoiding possibly stress-induced habits of grinding,
clenching, nail biting or biting on objects like pencils,
excessive gum chewing, biting and/or sucking on the lip
or cheek, and pressing and/or sucking on the tongue.
The patients were further informed that depending on
the outcome of the final diagnosis, treatment would start
at the second visit and would be based on one of four
possibilities: (i) occlusal appliance, (ii) slight occlusal ad-
justment, (iii) a combination of occlusal appliance and
slight occlusal adjustment, or (iv) physiotherapy of the
masticatory system. The possibilities of ‘slight occlusal
adjustment’ or its combination with ‘occlusal appliance’
were applied in another study (paper in preparation) in
which myogenous TMD patients with pronounced occlusal
interferences participated. In order to blind the patients
and clinicians at the initial visit about the treatment alloca-
tion following randomization, dental impressions necessary
to prepare dental casts for treatment options (i)-(iii) but not
(iv) (physiotherapy), were obtained from all patients.
The patients of the present study were, using computer-
generated random data, randomized by an independent
researcher, across two therapies: (1) occlusal splint ther-
apy, and (2) physiotherapy of the masticatory system
(Fig. 1). Physiotherapy was the active treatment which was
compared with a control treatment, occlusal splint ther-
apy. Block randomization was used with an intended
block size of 100 patients (90 were realized; Fig. 1) and an
allocation ratio of 1:1:1:1 for 4 subgroups, i.e. (1.1) splint
therapy for ‘younger’ patients (age ≤median age of 32 years;
expected median from ref [26]), (1.2) splint therapy for
‘older’ patients (age > 32 years), (2.1) physiotherapy for
‘younger’ patients, and (2.2) physiotherapy for ‘older’
patients. By considering these two age groups, a stratifica-
tion occurred across the therapy groups for age and
possibly related factors which might influence treatment
success, such as duration of pre-treatment pain and,
Table 1 Demographic and clinical variables before the start of treatment
Compliers Dropouts
Physiotherapy Splint therapy
Demography:
Number of patients [n] 37 35 18
Age [mean, yrs (SD)] 31.4 (9.6) 29.0 (9.6) 28.7 (9.0)
Sex [female %] 95% 91% 94%
With partner [patient %] 56% *n = 36 40% 50%
Housekeeping [main responsibility, patient %] 58% *n = 36 58% *n = 31 53% *n = 15
Outdoors activity [work/study; patient %] 83% *n = 36 82% *n = 33 69% *n = 16
Both outdoors and housekeeping [patient %] 47% *n = 36 57% *n = 30 36% *n = 14
Clinical data:
PM-patients [patient %] 69% *n = 36 82% *n = 33 80% *n = 15
Duration of PreTx pain [mean, months (SD)] *n = 17 25.6 (29.9) 18.2 (19.9) 27.3 (24.6) *n = 17
Duration of PreTx pain [median, months] 14 10 18 *n = 17
No spread of pain; only facial areas [patient %] 27% 34% 17%
Limited spread of pain; facial and neck areas [patient %] 5% 14% 11%
More extended spread of pain; facial, neck and shoulder areas [patient %] 68% 52% 72%
Predominant pain intensity, at the initial visit [mean, mm (SD)] 60.4 (22.4) 53.6 (13.1) 59.6 (18.8)
Predominant pain intensity, at start of Tx [mean, mm (SD)] 41.0 (23.4) 39.1 (22.5) 43.6 (20.2)
HR-QoL, EQ-5D [mean, utility value (SD)] 0.707 (0.202) 0.773 (0.176) *n = 32 *n = 0
Use of over-the-counter (OTC) medication:
Patient % 54% 39% *n = 33 67% *n = 15
Percentage of possible times of scoring [%-value, mean (SD)] 7.1 (9.9)§ 3.0 (5.2)§ *n = 33 16.5 (19.7)† *n = 15
dropouts: n = 10 for physiotherapy and n = 8 for splint therapy. PM, Post Meridian patients with a maximal VAS-score of pain intensity at dinner or bed time, from
a pain diary [23]. Spread of pain, data from the Pain Location Questionnaire [23]. HR-Qol, general Health-related Quality of Life using Euroqol-5D (EQ-5D). Use of
over-the-counter medication, data from a pain diary [23]. *cases of missing values with indication of the actual number of patients (n). Differences between groups
were only significant for the use of OTC medication, percentage of possible times of scoring. (§between complier groups, p < 0.05; †dropouts vs. compliers,
p < 0.05). All variables were obtained at the initial visit, except for ‘PM-patients’ and ‘use of OTC medication’ which were obtained during 2 weeks before
the start of treatment, from a pain diary, and for ‘Spread of pain’ and ‘HR-QoL’ which were obtained just before the start of treatment
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although not recent (>1 year), a previous treatment
for pain. This stratification ensured a similar distri-
bution of pre-treatment values from age-related fac-
tors in both patient samples which had a limited size
(n = 35–37compliers; Fig. 1).
Evaluation of a patient’s status was carried out not only
by the person who carried out treatment (the ‘clinician’, a
dentist for dental therapies and a physiotherapist for
physiotherapy), but also by an assessor (another dentist)
who was blinded to the type of treatment and the patient’s
medical history. Using data from the assessor, a third den-
tist, the investigator (author RG), determined the outcome
values of TDC, to keep the assessor blinded. When a
physiotherapist carried out treatment, a dentist who was
responsible for the patient, carried out a final evaluation
as ‘clinician’. Several clinicians and assessors were avail-
able, i.e. ten dentists and five physiotherapists as clinician
and four dentists as assessor. All abovementioned persons
were specialists in treatment of orofacial pain and TMD,
and were calibrated using a pilot group of 20 patients,
which was also used for tuning the cut-off value of TDC
(−0.379, see below) for distinguishing between a successful
treatment and an unsuccessful one [19]. Following
randomization for therapy, each patient was independ-
ently assigned to a particular clinician for treatment and a
blinded assessor for the entire procedure. The patients
were approximately stratified across the participating
clinicians and assessors.
A similar waiting time between the initial visit and
start of treatment occurred for both types of therapy,
i.e. on average 4.4 weeks (SD 2.6) for splint therapy and
4.4 weeks (SD 2.4) for physiotherapy. The waiting time
was at least 2 weeks to enable the scoring of a 2-week
pain diary [23], and the preparation of a maxillary,
flat-plane, hard acrylic occlusal appliance (Michigan
type) [27], for those patients who were assigned to
splint therapy.
General procedure of treatment and outcome
The score profile of the patients was determined using
data from an anamnestic and clinical examination. The
anamnestic questionnaire included scoring on adjectival
0–4 point scales of five items which were characteristic
for mygenous TMD (for details, also for the clinical
examination, see Appendix in ref [19]). The question-
naire also included scoring of the intensity of the pre-
dominant pain from the masticatory system on a
100 mm Visual Analogue Scale (VAS; anchor points: ‘no
pain’ and ‘the most intense pain one can imagine’). The
clinical examination included scoring of pain intensity
on an adjectival 0–4 point scale during jaw movements,
palpation of jaw muscles, and during clenching. The
total number of clinical items was 42. Regarding a
threshold of signs and symptoms at the initial visit and
the start of treatment, see Additional file 1, ‘Threshold of
signs and symptoms’.
Each therapy had a specific program with a number of
visits which could vary depending on the rate of a patient’s
improvement (see below, section ‘Specific treatment pro-
cedures, general features’). Hence with an inter-visit inter-
val which was therapy-specific, the duration of treatment
could vary. The progress and ultimate effect of treatment
were evaluated using the index ‘Treatment Duration
Control’ (TDC). Details of the TDC procedure (including
the use of added reference items), and on the validation of
TDC can be found elsewhere [19]. Only some main
features are presented below.
Baseline scores from anamnestic and clinical items were
obtained by a blinded assessor, just before treatment and
transferred by the investigator to keep the assessor
blinded. This baseline assessment occurred on average
4.4 weeks (SD 2.5) following the initial visit. Using
Smallest Detectable Difference (SDD) as a threshold,
items with significantly large score values were selected
as ‘reference items’ for monitoring relative change using
the index TDC during treatment (by the clinician) and
during follow-up (by the investigator, based on data
from the blinded assessor).
The clinician carried out the anamnestic and clin-
ical examination of the patient during the various
treatment visits. The relative change in each reference
item, between a later visit and the reference visit, was
expressed as a contrast value, being the ratio between
the difference and the sum of both score values of
the reference item. The index TDC is the mean
across all contrast values from the various reference
items. TDC values vary within a range from +1.000
to −1.000, in which 0 represents no change, −1.000
represents complete recovery and a positive value
represents worsening.
The clinician’s decision to continue or end treat-
ment, thus controlling treatment duration, was based
on two cut-off points of TDC. Each cut-off point cor-
responds to a global relative decrease of the scores of
reference items. The first cut-off point was TDC =
−0.212, which corresponds to a decrease of 35% in a
single score of pain intensity at a 100 mm VAS. A
less negative value than -0.212 means less change to-
wards recovery. If, at a critical stage of treatment, a
patient’s TDC was larger than −0.212 (less negative,
more to zero), the patient was insufficiently responsive
to treatment. The second cut-off point, TDC = −0.379,
was related to attaining functional status for myogenous
TMD (potentially ‘successful’ treatment with a residual
level of signs and symptoms), and corresponds to 55% de-
crease of a single score of pain intensity. Depending on
the TDC-outcome, the clinician continued or finished
van Grootel et al. BMC Musculoskeletal Disorders  (2017) 18:76 Page 6 of 17
treatment within the limits of possible number of visits
and their therapy-specific intervals. If TDC was > −0.212
after a therapy-specific minimum number of treatment
visits, the treatment was ended because the patient was
not sufficiently responsive. If −0.379 < TDC ≤ −0.212, a
patient was sufficiently responsive but the treatment
was continued as long as the maximal number of
visits was not exceeded. If TDC was ≤ −0.379 at two
successive visits, treatment was ended as being poten-
tially successful.
Patients whose treatment was potentially successful or
unsuccessful according to the findings of the clinician,
were transferred to the assessor for blinded evaluation.
The assessor carried out the anamnestic and clinical
examination, on average 3.6 weeks (SD 6.0) after the end
of treatment for all patients. The waiting time between
the end of treatment and the first post-treatment visit
for blinded evaluation was at least 2 weeks to enable the
scoring of a 2-week pain diary [28]. For ethical reasons,
patients with an unsuccessful treatment in the short-
term, according to the data from the assessor, had no
follow-up. Their initial unsuccessful treatment was im-
mediately followed by another treatment (stepped-care).
The other patients (successful treatment in the short-
term) had a follow-up of 6 months and the follow-up
was continued for another 6 months (thus 12 months
follow-up in total) for those patients whose treatment
was still successful after 6 months. The investigator
determined post-treatment TDC-values for each patient
using solely data from the blinded assessor.
Following the introduction of all score values in a
custom-made spreadsheet (Microsoft Excel®; available on
request) the reference items were automatically detected
and all TDC-values were automatically determined for
each patient.
Specific treatment procedures, general features
For each type of treatment, a usual bandwidth of pos-
sible visits and their intervals was defined a priori.
For splint therapy, the adaptive program (Additional
file 1, ‘Rules for progressing and ending splint ther-
apy’) could result in a number of visits and a treat-
ment duration which varied within a range of 3–6
(visits) and 12–30 weeks (duration). For physiotherapy
(Additional file 1, ‘Rules for progressing and ending
physiotherapy’), the possible number of visits varied
within a range of 10–16 and the treatment duration
within a range of 10–21 weeks. Although the visit program
was respected as much as possible, like in usual clinical
care, this program could somewhat be adapted in view of
holidays, illness or limitations of appointment opportun-
ities. The rules from the Additional file 1 for progressing
and ending therapy were transformed to decision trees
to provide an overview of a patient’s treatment to the
clinician.
Specific treatment procedures, splint therapy
For patients who were assigned to splint therapy, the oc-
clusal appliance (Michigan type) was applied in the
upper jaw, and the patient was instructed to wear the
splint as much as possible, at least in the evening and
overnight for a minimum of 10 to 12 h. During treat-
ment, the clinician determined the patient’s status every
6 weeks by anamnestic and clinical examination and by
determining TDC. Patients could, if needed, have a short
interim visit for minor adjustment of the splint.
As soon as the patient’s signs and symptoms decreased
sufficiently, as indicated by TDC ≤ −0.379, the splint was
gradually withdrawn during the forthcoming 6 weeks,
i.e. by wearing the splint for 6 nights during the first
week of withdrawal, five nights during the second week
etc. If the patient’s signs and symptoms remained suffi-
ciently low, thus if TDC ≤ −0.379 occurred at two succes-
sive visits corresponding to an entire period of 12 weeks,
the clinician considered the splint therapy as being poten-
tially successful and the patient was referred to the blinded
assessor who applied the abovementioned outcome pro-
cedure. Otherwise, the clinician ended the splint therapy
as unsuccessful and such a patient was also referred to the
assessor. Patients whose splint therapy was ended success-
fully were allowed to apply splint wearing again if they felt
a need.
Specific treatment procedures, physiotherapy
The aim of physiotherapy was learning techniques to (1)
avoid stress related pain from the masticatory system
and (2) relieve this pain by means of self-massage and
relaxation. During the first 3 weeks, all patients partici-
pated 2–3 times a week in an intensive program with in-
structions and exercise regarding (on indication): (i)
posture of head, neck, shoulders, jaw and tongue, and
(ii) opening movement of the jaw, with control of rota-
tion and translation, (iii) progressive relaxation of jaw
muscles using the method of Jacobson,(iv) counselling
on avoiding excessive jaw opening, and habits like biting
on objects and unilateral chewing, (v) pain relieve by
means of self-massage of sore or painful facial and/or
jaw muscles, (vi) stretching of jaw-closing muscles intra-
orally by using the thumb, and resisting jaw-opening by
placing the hand under the chin, by which jaw-closing
muscles are relaxed while jaw-opening muscles are acti-
vated, (vii) habit-reversal techniques for avoiding habits
like nail-biting, lip biting, biting on, for example, pencils,
clenching or grinding, or sucking on the tongue and
(viii) mostly at the end of the program, enhancement of
the capacity of loading the muscles by chewing different
types of foods and chewing gum.
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Following the basic program of 3 weeks, patient-specific
exercises were continued at home for 6 weeks, for those
patients whose signs and symptoms has decreased suffi-
ciently, as indicated by TDC ≤ −0.379. Otherwise, a
patient-specific program was continued with weekly
controls with a maximum of 6 weeks (for details, see
Additional file 1, ‘Rules for progressing and ending physio-
therapy’). As soon as TDC ≤ −0.379 was attained at such a
control, home exercise was carried out for 6 weeks.
Following 6 weeks of home exercise the patient was clinic-
ally examined by the responsible dentist (who acted then
as ‘clinician’). If TDC ≤ −0.379, the physiotherapy was con-
sidered as being potentially successful and the patient was
referred to the blinded assessor who applied the outcome
procedure. Otherwise, the patient returned to the physio-
therapist for one additional period of home exercise
during 6 weeks after which final clinical evaluation was
carried out. Patients whose physiotherapy was ended suc-
cessfully were allowed to apply home exercise again if they
felt a need.
A stepped-care model
Using stepped-care, patients whose splint therapy was
unsuccessful continued with physiotherapy and reversely.
In order to limit the project duration, the subsequent
treatment was part of common care and thus not con-
trolled by TDC. However, a theoretical stepped-care
model has been developed to assess the overall suc-
cess rate of a trajectory of one therapy or two succes-
sive therapies if stepped-care is necessary (for details,
see Additional file 1, ‘A stepped-care model including
two possible therapies’) [29].
The overall percentage success rate of a trajectory
(SRtr) of a therapy A which is possibly followed by a
second therapy B, is given by:
SRtr = (fA,S + m. fB,S – m. fA,S. fB,S).100% (equation (6) in
Additional file 1), in which fA,S and fB,S are fractions of
patients for which therapy A and B respectively are
successful when applied separately (thus without a pre-
ceding therapy A when therapy B is applied). Each of
these fractions equals the basic percentage success rate
(SRA or SRB) divided by 100. m is a modulation factor
which describes the possible influence of a preceding
therapy A on the basic success rate of therapy B (m ≥ 0).
Outcome variables of the RCT
The primary outcome variables were: (i) number of
visits/duration of treatment used which is based on
TDC during treatment, (ii) success rate based on post-
treatment TDC, and (iii) effectiveness based on post-
treatment TDC. While number of visits/duration of
treatment were known at the end of treatment, success
rate and effectiveness were determined following treat-
ment, i.e. after on average 3.6 weeks, and for patients
whose treatment was successful in the short-term, also
after 6 and 12 months. Weighing of these primary
outcomes enabled a decision on whether physiotherapy
or splint therapy may be recommended as an initial
treatment of myogenous TMD in stepped-care.
Success rate was determined for each therapy group
using the criterion TDC ≤ −0.379. Furthermore, the
mean and SD of the post-treatment TDC values were
determined for each therapy group for comparing ther-
apy effectiveness in terms of relative decrease in scores
from significantly pronounced signs and symptoms
which are patient-specific [19]. Mean TDC-values from
the last post-treatment visit were used as a measure of
effectiveness. Four out of 72 patients whose treatment
was successful in the short-term (three patients for
splint therapy and one patient for physiotherapy) could
not be reached for the 1-year follow-up, although their
treatment was successful at an earlier post-treatment
stage, i.e. following treatment (one patient) or after a
follow-up of half a year (three patients). Using an intent-
to-treat analysis, the last post-treatment observation was
carried forward thus missing values during the follow-up
were replaced with the last previous non-missing value.
Because of a lack of comparable outcome TDC-values
to date, the intensity of predominant pain of the masti-
catory system has been used as a key parameter to com-
pare therapy effectiveness of the present study with that
from other studies (cf. Discussion). This secondary out-
come variable was determined at the initial visit (on
average 4.4 weeks before the start of treatment), at the
start of treatment, and following treatment, i.e. on aver-
age after 3.6 weeks, and for patients whose treatment
was successful in the short-term, also after 6 and
12 months. Pain intensity has been analysed in a trad-
itional manner, i.e. by comparing its pre- and post-
treatment values and by determining effect size (Cohen’s
d) for each therapy using an online effect size calculator
[30]. The change in the mean of raw scores of an out-
come variable observed after an intervention of known
effectiveness is an estimate of Clinically Important Dif-
ference (CID) [31]. In order to characterize the effect of
interventions in general, this change, normalized as a
percentage of the scale range (scale-% units), was de-
noted as the Clinical Difference (CD). Cohen’s d is the
ratio between the non-normalized CD and the pooled
SD of the scores from two times of measurement.
Cohen’s d was bias corrected [32]. Values of d between
0.20 and 0.49 represents a small effect of treatment,
those between 0.50 and 0.79 a medium effect, and those
equal to or larger than 0.80 correspond to a large effect.
As the initial treatment of a substantial fraction of the
patients became unsuccessful (cf. Results), it was
explored whether some subgroups of myogenous TMD
patients may respond better to physiotherapy or splint
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therapy than other ones. Possible differences in pre-
treatment values of variables were therefore exam-
ined between groups for which treatment became
successful or unsuccessful respectively. To that end,
variables were used with gradual levels for which the
number of patients in the sub-samples was still fairly
large (n = 14–21). Apart from the demographic vari-
able ‘age’, these differences were examined for the clinical
variables, ‘duration of pre-treatment pain’, ‘pain intensity’,
‘Health-related Quality of Life’ and ‘number of times of use
of OTC-medication’ (Table 1). Furthermore, such possible
differences were examined for 20 psychosocial variables, in-
cluding those related to anxiety, depression, health locus of
control and coping style (cf. Table 4 in ref [23]).
Statistical analysis
Statistical analyses were performed using Graphpad soft-
ware (Graphpad Prism 6.04; Graphpad Software Inc., San
Diego, CA). Differences in frequency between two patient
groups were examined using a squared-Chi test or Fisher’s
exact test. A Student’s t-test for paired observations was
used for examining intra-subject differences in values of
continuous variables from two times of measurement, and
a Student’s t-test for unpaired observations for inter-
subject differences in values obtained at one occasion. The
values of ‘duration of pre-treatment pain’ which were not
normally distributed and positively skewed, were first log
transformed. One-way ANOVAs were used when four
patient subgroups were involved in one factor, for ex-
ample, post-treatment TDC-value. Because the variance of
individual TDC values depends on the number of contrib-
uting items [19], it was examined whether the distribution
of contributing items was similar between different patient
groups for enabling an unbiased statistical comparison
between group means of TDC. Two-ways ANOVAs were
used when two factors with 2–4 levels were involved, i.e.
stage of treatment (four levels, paired observations) and
either type of therapy or success outcome (two levels,
unpaired observations). When a two-way ANOVA was
significant at a level of 2.5% (Bonferroni correction of a
5% significance level for the two-fold use of data in these
ANOVAs), Bonferroni’s multiple comparison tests were
used to determine significance of differences between
pairs of conditions. The level of significance was 5% other-
wise. A u-test was used for examining whether mean
post-treatment TDC-values differed from zero and were
more negative, indicating an improvement of signs and
symptoms at a group level.
Results
Table 1 shows the pre-treatment values of demographic
and clinical variables. Except for the small percentage of
times of using OTC-medication (3.0–7.1%), significant
differences of the other 16 variables did not occur
between the two therapy groups of patients who com-
pleted the entire procedure, and between the compliers
and the dropouts. When patients who did not use OTC-
medication were excluded in the analysis, the percentage
of times of using this medication only tended (p = 0.059)
to be larger for patients who completed the procedures
for physiotherapy rather than for splint therapy (physio-
therapy: 13.1% of the possible times, SD 10.1, n = 20;
splint therapy: 7.7%, SD 5.7, n = 13).
Table 2 shows that the success rate (SR) of physiother-
apy was similar to that of splint therapy, in the short-term
(at EM: 73–83% of the patients) as well as in the long-
term (LM: 51–60%). The Relative Risk (RR: a probability
of which its value equals the ratio between SRs from
physiotherapy and splint therapy) was 0.88 at EM (95%
confidence interval: 0.69–1.13) and 0.86 at LM (95% con-
fidence interval: 0.57–1.30). Hence, patients treated with
physiotherapy were 12% (EM) and 14% (LM) respectively
less likely to have a successful treatment rate than with
splint therapy, but this is not statistically significant. The
SR outcomes were attained with a significantly (p < 0.001)
shorter treatment duration for physiotherapy (on aver-
age 10.4 weeks less) and, on the other hand, a signifi-
cantly (p < 0.001) smaller number of treatment visits
for splint therapy (on average 7.1 visits less).
Table 3 shows that the TDC-values in the long-term
(therapy effectiveness) were similar for physiotherapy
and splint therapy, regardless of the patient group (all
patients, or patients whose treatment was successful or
unsuccessful). The mean TDC-values were always sig-
nificantly (p < 0.001–0.01) smaller (more negative) than
zero, even for patients whose treatment was unsuccess-
ful indicating improvement of signs and symptoms in
these patients.
As a possibly unintended effect, new signs and symp-
toms of myogenous TMD could appear during a pa-
tient’s treatment, which did not occur at the start of
treatment. If significant, the scores of such signs and
symptoms were included in added reference items of the
TDC-procedure [19]. The frequency of cases with added
items during treatment was similar between physiother-
apy (11 out of 37 patients; 30%) and splint therapy (11
out of 35 patients; 31%). For both types of therapy,
added items occurred significantly (p < 0.05) less fre-
quently in patients whose treatment became successful
in the long-term than for patients with an unsuccessful
treatment. While only 10% of the patients (two out of
19) whose physiotherapy was successful had added
items, this frequency was 50% (nine out of 18) for the
patients with unsuccessful physiotherapy. For splint
therapy, these frequencies were 14% (three out of 21 pa-
tients) and 57% (eight out of 14 patients) respectively.
However, the occurrence of added items never yielded
cases of an interrupted treatment.
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The post-hoc power of the present study to detect
inter-therapy differences in mean TDC values is fairly
large, i.e. 68% for detecting a TDC-difference of 35.0 and
80% for detecting a difference of 40.0%. These detectable
differences in multidimensional TDC-values are equiva-
lent to changes of 19.7–29.7% in the difference of a
single variable, like ‘pain intensity’, before and after treat-
ment (cf. Additional file 1, ‘Post-hoc power analysis on
measures of effectiveness’).
Table 4 (top) shows that the intensity of the predominant
pain from the masticatory system decreased signifi-
cantly (p < 0.001; stage effect in a 2-way ANOVA) in
the long-term. This decrease was similar for both therap-
ies (cf. Additional file 1: Table S6, ‘Two-way ANOVA stat-
istical analysis for pain intensity’). The decrease in the
means of pain intensity between the start of treatment
and the last post-treatment measurement, the Clinical
Difference (CD), was 21.8 scale-% for physiotherapy and
27.6 scale-% for splint therapy. These CD-values corre-
sponded to Cohen’s d-values of 0.86 and 1.39 respectively
(Table 4, bottom).
For a post-hoc power analysis regarding pain intensity,
individual difference values were considered between the
last post-treatment measurement and the start of treatment
(cf. Additional file 1, ‘Post-hoc power analysis on measures
of effectiveness’). The power is 39% for detecting an inter-
therapy difference of 35.0% in the mean difference value of
pain intensity, and 80% for detecting a difference of 58.4%.
Even before treatment, between the initial visit with
counselling and the start of treatment, pain intensity
decreased significantly (p < 0.0001–0.01) and similarly
for both therapy groups (Table 4, top). CD was 19.4 and
14.1 scale-%, and Cohen’s d was 0.84 and 0.77 for
patients assigned to physiotherapy and splint therapy
respectively (Table 4, bottom).
Whereas Cohen’s d of decrease in pain intensity
between the start of treatment and the last post-
treatment measurement, was significantly smaller for
all patients with physiotherapy than for those with
splint therapy (0.86 vs. 1.39; Table 4 bottom), these
d-values were similar (2.07 vs. 2.02) for patients
whose treatment was successful. For patients whose
treatment was unsuccessful, the d-values were similar
as well, i.e. d was 0.39 for physiotherapy (95% confi-
dence interval: −0.27–1.05) and d was 0.73 for splint
therapy (95% confidence interval: −0.04–1.49).
Table 2 Success rate, treatment duration and number of visits
Phyiotherapy Splint therapy P-value and significance of difference
Number of patients 37 35
SR (% patients) at EM 73% 83% 0.339 NS†
SR (% patients) at LM 51% 60% 0.487 NS†
Duration of treatment [mean, weeks (SD)] 13.8 (6.5) 24.2 (9.2) p < 0.0001‡
Number of visits [mean, (SD)] 11.5 (2.0) 4.4 (1.1) p < 0.0001‡
SR, success rate. EM, end-measurement of treatment outcome in the short-term, at the first post-treatment visit. LM, last measurement of treatment outcome in
the long-term, at the last post-treatment visit. LM only includes an entire follow-up of 1 year for patients whose treatment continues to be successful from EM.
number of visits: from the first visit of treatment (thus excluding the initial visit with intake) to the visit with the last control by the clinician included. † squared-
Chi test. ‡ Student’s t-test for unpaired observations
Table 3 Post-treatment TDC values in the long-term
Physiotherapy Splint therapy P-value and significance of difference
All patients:
TDC at LM [mean (SD), n] −0.512 (0.339), 37 −0.575 (0.361), 35 0.446 NS†
Number of items contributing to TDC at LM [mean (SD), n] 14.2 (6.6), 37 15.7 (8.3), 35 0.407 NS†
Patients with STx:
TDC at LM [mean (SD), n] −0.807 (0.127), 19 −0.820 (0.161), 21 0.808 NS‡
Number of items contributing to TDC at LM [mean (SD), n] 12.2 (5.9), 19 15.6 (9.2), 21 0.152 NS§
Patients with UTx:
TDC at LM [mean (SD), n] −0.200 (0.161), 18 −0.208 (0.244), 14 0.906 NS‡
Number of items contributing to TDC at LM [mean (SD), n] 16.3 (6.8), 18 15.7 (7.0), 14 0.832 NS§
TDC at LM, last measurement of treatment outcome in the long-term. STx and UTx, successful and unsuccessful treatment respectively. †Student’s t-test for
unpaired observations. NS, non-significance. ‡one-way ANOVA for the factor TDC between the various patient groups with different therapies and treatment
outcomes. The factor TDC was significant (p < 0.0001), indicating TDC-values which were smaller for patients with STx (more negative TDC-values indicating more
improvement) than for patients with UTx. The Bonferroni’s multiple comparison tests were non-significant between both therapies, for STx and UTx respectively
(p-values indicated). §one-way ANOVA for the factor number of items contributing to TDC at LM which was non-significant (p = 0.328)
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For both therapy groups, Fig. 2 shows the pain inten-
sity as a function of time for the two subgroups of pa-
tients, i.e. patients whose treatment was successful (STx)
or unsuccessful (UTx) in the long-term. Figure 2 depicts
a decrease in pain intensity between initial visit and start
of treatment, for the four subgroups of patients. Physio-
therapy and splint therapy attained similar end levels of
pain intensity which were significantly higher in patients
with UTx than in patients with STx (see Additional file 1:
Table S7, ‘Two-way ANOVA statistical analysis for pain in-
tensity’). The time needed to attain these similar end levels
was shorter for physiotherapy than for splint therapy.
Regardless of the type of therapy, pain intensity not only
decreased significantly between start and end of treatment
in patients with STx but also in patients with UTx. In pa-
tients with UTx, this decrease halted at a higher end level
than that of patients with STx. For patients with UTx, the
higher level at the end of treatment, stage E-Tx, was simi-
lar to the post-treatment level at EM (Fig. 2), on average
3.6 weeks later. For both types of therapy, pain intensity of
patients with STx was similarly small at the post-
treatment stages EM and LM (Fig. 2; no significance in a
Student’s t-test for paired observations).
In order to explore which factors might decrease a
patient’s responsiveness to a therapy, the baseline levels
of several factors have been compared between patients
whose treatment became successful and unsuccessful re-
spectively. Regardless of splint therapy or physiotherapy,
significant differences between both patient groups did
not occur for the various clinical variables examined, in-
cluding ‘number of times of use of OTC-medication’,
which differed between the entire therapy groups at
baseline (Table 1). It is therefore notable that the fraction
of patients who used this medication was not significantly
Fig. 2 Intensity of predominant pain in the masticatory system. This
intensity (mm on a 100 mm VAS) is depicted as a function of time
for two types of therapy, two treatment outcomes according to
TDC (successful treatment, STx; unsuccessful treatment, UTx), and
the various pre-treatment and treatment stages. Mean and SEM are
depicted for pain intensity as well as the timing of the stages. Stages: I,
initial visit; St-Tx, start of treatment (corresponding with the zero point of
time); E-Tx, end of treatment; EM, end measurement of treatment at the
first post-treatment visit; LM, last measurement from patients with a
successful treatment, following a 1-year-follow-up. For statistical testing
of the various levels of pain intensity, see Additional file 1: Table S7
Table 4 Predominant pain intensity from the masticatory system at three stages
Pain intensity per therapy group:
Physiotherapy (n=37) Splint therapy (n=35)
Initial
visit
Start-Tx LM Initial
visit
Start-Tx LM
[mean (SD)] [mean (SD)]
60.4 (22.4) 41.0 (23.4) 19.2 (26.4) 53.6 (13.1) 39.1 (22.5) 11.5 (16.2)
Cohen’s d between stages, per therapy group:
Physiotherapy Splint therapy
d Confidence
interval (95%)
d Confidence
interval (95%)
Initial visit
vs start-Tx
0.84 0.36–1.31 0.77 0.29–1.26
Start-Tx
vs LM
0.86a 0.39–1.34 1.39a 0.87–1.92
Initial visit
vs LM
1.66b 1.13–2.19 2.83b 2.17–3.49
Top: mean pain intensity in mm on a 100 mm VAS and SD (between brackets) for predominant pain at three stages: initial visit, start of treatment (Start-Tx) and at
the last post-treatment visit, last measurement (LM). Both therapy groups have a similar significant stage effect (p<0.0001; 2-way ANOVA, cf. Additional file 1:
Table S6). All inter-stage differences are significant (p<0.0001-0.01) in Bonferroni’s multiple comparison tests
Bottom: d, Cohen’s effect size based on pooled SD (d=(|mean2-mean1|)/SDpooled, in which ‘2’ refers to the later stage and ‘1’ to the earlier one), and bias corrected
(Hedges). For the values of the means, see top. a,b significant differences of d between therapy groups as the means are mutually excluded from the confidence
interval of the other therapy group
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related to treatment outcome (physiotherapy: eight out of
19 patients with a successful treatment (42%), used OTC-
medication, and 12 out of 18 patients with an unsuccessful
treatment (67%); splint therapy: ten out of 21 patients with
a successful treatment (47%), and three out of 14 patients
with an unsuccessful treatment (21%)).
Significant differences were also, in general, absent for
the various psycho-social variables examined. Only one out
of 20 psycho-social variables differed significantly (p < 0.05),
i.e. internal locus of control for physiotherapy which was
4.74 (SD 0.81, n = 19; questionnaire ‘Multidimensional
Health Locus of Control’, MHLC [23]) for patients whose
treatment was successful and 3.94 (SD 1.20, n = 17, 1 miss-
ing value) for patients with an unsuccessful treatment.
Physiotherapy and splint therapy were considered in
the stepped-care model. Table 5 shows the success rate
of each of the two possible trajectories, SRtr, for three
values of the factor m, which modulates the basic
success rate of the second possible therapy in a trajec-
tory, thus describing the influence from the preceding
therapy. For m= 1 (no change in success rate of the sub-
sequent therapy), SRtr is 80.5% of the patients, regardless
of the sequence in which the two therapies are applied.
For m= 0.5 (halving the basic success rate of the subse-
quent therapy), SRtr is 10.2–14.7 patient-% units smaller
than SRtr for m= 1. The largest value of SRtr occurs with
m= 0.5 when the trajectory is started with splint therapy
for which, although not significant, the observed value of
the basic success rate is larger than that for physiotherapy,
i.e. 60% vs 51% (Table 2). However, the difference in suc-
cess rate between the two possible trajectories with
reversed therapy sequences, 4.5%, is smaller (half in this
example) than the difference, 9%, in basic inter-therapy
success rate (cf. equation (11) in Additional file 1, ‘A
stepped-care model including two possible therapies’). For
m= 1.5 (enhancing the basic success rate of the subse-
quent therapy by this factor), SRtr is 10.2–14.7 patient-%
units larger than SRtr for m = 1, and, in contrast with
m = 0.5, the largest value of SRtr occurs when the tra-
jectory is started with the therapy with the smaller value
of success rate, hence physiotherapy. The difference in
success rate between the two possible trajectories, 4.5%, is,
like for m= 0.5, also smaller than the difference in basic
inter-therapy success rate.
Discussion
Effect of Counselling on Pain Intensity
Like in a traditional RCT, stringent inclusion and exclu-
sion criteria were applied to select myogenous TMD pa-
tients. In contrast to previous RCT studies on myogenous
TMD patients [14, 15, 18, 33, 34], the entire treatment
procedure using TDC was similar to one in general clin-
ical care. This procedure included counselling, a therapy-
and-patient-specific duration of treatment, and possibly
intermediate adjustment of an occlusal splint. Further-
more, patients whose therapy was successful were allowed
to apply splint wearing or physiotherapy (home exercise)
respectively when they would feel a need. The influence
on pain intensity of the standardized reassurance and
counselling which preceded both types of therapy, will
first be discussed, followed by the influence of treatment
on pain intensity. The post-treatment TDC-values will be
discussed thereafter.
The intensity of the predominant pain from the masti-
catory system decreased on average 32% between the
initial visit (100%) and the start of treatment with a CD
of 16.6 scale-%. The value of Cohen’s d, on average 0.80,
reflects a moderate/large effect of counselling on pain
intensity. Pain intensity was constant in a pain diary,
during 2 weeks before the start of treatment [23]. Hence,
the decrease of pain intensity occurred shortly after
counselling rather than late in the waiting period of
4.4 weeks.
Regarding other studies, in a heterogeneous sample of
TMD patients [35], pain intensity decreased similarly by
34% (CD: 22.8 scale-%), with an effect size d of 1.13 (mean
and SD values of d derived from a Figure), following coun-
selling and a waiting period of 2 weeks. A similar decrease
of 15.4% (CD 10.1 scale %, d: 0.73) of pain intensity was ob-
served 1 month following initial visit and solely counselling,
during maximum unassisted jaw opening in myogenous
TMD patients whose jaw opening was limited (RDC/TMD:
class 1b) [36].
Table 5 Success rate in stepped-care of trajectories consisting of one or two therapies
Trajectory
Physiotherapy possibly followed
by splint therapy
splint therapy possibly followed
by physiotherapy
difference between trajectories
SRtr for m= 1 (patient %) 80.4% 80.4% 0.0%
SRtr for m= 0.5 (patient %) 65.7% 70.2% 4.5%
SRtr for m= 1.5 (patient %) 95.1% 90.6% 4.5%
SRtr, success rate of a trajectory. A trajectory consists of a first therapy which is possibly followed by a second therapy if the first one is unsuccessful. SRtr has been
calculated for the two possible sequences of physiotherapy and splint therapy, according to the stepped-care model (equation (6) in Additional file 1, ‘A stepped-
care model including two possible therapies’), using the basic success rates of these therapies (cf. Table 2, at stage LM) and three values for the modulation factor
m, which reflects the degree by which the success rate of the second therapy is diminished (m < 1) or enhanced (m > 1)
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Because of a general association with pain and the de-
crease of pain intensity following counselling, the signs
and symptoms of one patient assigned to physiotherapy
decreased below the threshold following the initial visit,
so that this patient became a dropout. Hence, for
patients with a low level of signs and symptoms at the
initial visit, treatment may be restricted to counselling
and instructing simple stretch and auto-massage tech-
niques. A future application of the TDC-procedure from
the initial visit will be of interest to determine objectively
for which patients counselling and education will be suf-
ficient to attain functional status.
Effect of Treatment on Pain Intensity
Because counselling at the initial visit causes a fast decrease
in pain intensity which stabilizes, a further decrease must
be due to the applied therapy, rather than to a natural
course of the disorder. Cohen’s d was 0.86 and 1.39 for
physiotherapy and splint therapy respectively. Thus the
effect on pain intensity of these therapies which were
controlled by the TDC-procedure is large (d > 0.80). These
d-values and the CD-values (21.8–27.6 scale-%) are similar
to those from previous studies on mainly myogenous TMD
patients without overt psychosocial factors, regardless of
the type of pain of which the intensity was considered. In
these previous studies [14, 15, 33, 34, 37], the effectiveness
of either physiotherapy or splint therapy has been examined
using a constant treatment duration between 5 and
10 weeks, and treatment was preceded or combined with
counselling including reassurance of the patients. Following
splint therapy, CD of maximal pain was 23.2 scale-% (final
evaluation after 5 weeks, active splint group) [33] and 28.8
scale-% (12 months) [14, 15] and d was 0.99 and 1.48
respectively. Following physiotherapy, CD of present pain
was 22.5 scale-% for intra-oral physiotherapy alone and
34.9 scale-% for a combination of such physiotherapy and
education (12 months) [34]. In another study on physio-
therapy (6 weeks, combined groups) [37], CD was 25.4
scale-% for maximal pain and d was 1.35. The number of
treatment visits (10–18) in the previous studies on physio-
therapy was similar to the ones in the present study (mean
11.5 visits, SD 2.0). The number of treatment visits for
splint therapy was five in the study of Raphael and Marbach
[33] which is similar to the mean one in the present study
(4.4 visits), and at least two visits in the study of Ekberg
et al. [15]. The number of visits from the previous studies
on splint therapy does not include additional visits for a
withdrawal of wearing the splint when splint therapy
became successful. Treatment durations of 5–10 weeks in
these studies are therefore a lower limit of a realistic
duration.
The abovementioned findings show that when splint
therapy is preceded or combined with counselling
including reassuring the patients, this therapy has a large
effectiveness which is similar to that of physiotherapy
from separate studies. However, without such counsel-
ling, there was no effect of splint therapy on pain inten-
sity [18]. Following 3 months of splint therapy (6 visits
with only splint control), CD for intensity of spontan-
eous muscle pain was −2.8 scale-% and Cohen’s effect
size (ES: ratio between difference in means and baseline
SD) was merely −0.14 (negative sign: slight worsening).
An effect of solely splint therapy was also lacking for
pain intensity during gum chewing [18], i.e. CD was 3.4
scale-% and ES was 0.11. The effect of solely counselling
and education which was repeated 6 times during
3 months was moderate for intensity of spontaneous
muscle pain [18], i.e. CD was 11.2 scale-% and ES was
0.58 and small for pain intensity during gum chewing
(CD: 7.0 scale-%, ES: 0.30). Thus all findings suggest that
a synergy occurs between counselling and splint therapy,
i.e. absence of counselling blocks the potential effect of
splint therapy and/or splint therapy enhances the effect of
counselling. Because the effect of a one-time counselling
at the initial visit was stabilized in the present study before
splint therapy was started, blocking of the effect of splint
therapy is probably involved anyhow.
The small/moderate effect of solely counselling during
3 months was reflected in a relatively large VAS-score of
intensity of spontaneous muscle pain (30 mm on a
100 mm VAS) or pain following chewing (38 mm) at the
end of the program [18]. Such end levels of pain intensity,
which are even higher than the mean ones for patients
whose treatment was unsuccessful in the present study
(Fig. 2), are much higher than that of patients with a suc-
cessful treatment, who have attained functional status
(mean pain score < 7 mm; Fig. 2). Hence, solely counsel-
ling and education will, in general, not be sufficiently
effective to attain functional status within a reasonable
time. This conclusion is reinforced by findings from an-
other study on myogenous TMD patients (RDC/TMD:
class 1b) [34]. Although monthly counselling continuously
decreased the intensity of pain at maximum unassisted
mouth opening, this intensity was still large following
3 months (43 mm) and 12 months (27 mm). The large
effectiveness which was observed for physiotherapy in the
present study might in part be due to a repeated edu-
cation procedure which is inherently part of this type
of physiotherapy.
In the present study, Cohen’s d of pain intensity was
significantly larger for splint therapy (d = 1.39) than for
physiotherapy (d = 0.86), for the entire therapy groups.
However, the inter-therapy d-values were similar for the
sub-samples of patients whose treatment was successful
(d = 2.02–2.07) or unsuccessful (d = 0.39–0.73). The lar-
ger overall d-value for splint therapy reflects a value of
success rate for splint therapy which, although not
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significant, was slightly larger than that for physiother-
apy (Table 2). Thus slightly more patients with a suc-
cessful treatment and therefore a larger d-value,
contribute to the overall d-value of splint therapy.
TDC outcome of effectiveness and success rate
Advantages of considering the post-treatment TDC out-
come as a measure of effectiveness are an involvement of
scores from various signs and symptoms of myogenous
TMD rather than from solely pain intensity, and therefore
also more statistical power to detect possible inter-therapy
differences. The similar mean post-treatment TDC-values
for physiotherapy and splint therapy (−0.512– −0.575,
Table 3) indicate a similar effectiveness and a large effect
size (TDC < −0.379) for both types of therapy. The post-
treatment TDC-values were also similar between both
therapies, in subgroups of patients for which treatment
was successful or unsuccessful. The post-treatment TDC-
values for patients whose treatment was unsuccessful
(−0.200– −0.208) which were larger (less negative) than
others, differed nevertheless significantly from zero (TDC= 0
means no change). Thus even in patients whose treatment
was unsuccessful, their signs and symptoms improved signifi-
cantly and similarly for both therapies. The success rate
based on post-treatment TDC-values from individual pa-
tients is also similar between both therapies, i.e. 73–83% in
the short-term and 51–60% in the long-term (Table 2).
Considerations on Success Rate of Therapies
Patients with mainly basic signs and symptoms of myo-
genous TMD were selected in the present study. This
selection is reflected in mean baseline values of various
psycho-social factors which, in general, correspond to a
low degree of involvement [23]. Significant differences
did, in general, not occur between these baseline values
for patients whose treatment became successful or
unsuccessful respectively. Only internal locus of control
differed for physiotherapy, i.e. patients whose physio-
therapy became successful believed more that own
health is controlled by their own behaviour than patients
whose physiotherapy became unsuccessful. This out-
come may be related to the degree of the patients’ active
participation during physiotherapy. The difference in
mean score level was however small, i.e. 9.2% with
respect to the mutual mean. Baseline values of age or
clinical variables from the present study did also not
influence a patient’s responsiveness to a therapy. Regard-
less of the type of therapy, a modest use of OTC-
medication (mean: 3–7% of the times of scoring) is not
specifically related to any of the two treatment outcomes
(successful/unsuccessful). Although larger patient groups
are needed for more power in testing frequencies, this
finding suggests that such a modest use may have only a
small influence on success rate.
Despite a selection of ‘basic’ myogenous TMD
patients, the success rates in the short-term (73–83%)
were similar to that reported in text books for TMD in
general [1, 38, 39]. The success rates in the long-term
(51–60%) were such that a large fraction of the pa-
tients, on average 44%, still needed a subsequent treat-
ment, regardless of the type of initial therapy. In
contrast to previous studies, profoundly confounding
factors which might hamper an improvement in central
pain mechanisms, were excluded in the present study.
A patient’s treatment may therefore become unsuccess-
ful merely because the patient’s speed of recovery is
intrinsically low. Post-treatment TDC-values indicate
that even for patients whose treatment is unsuccessful,
their TMD signs and symptoms have improved signifi-
cantly. This improvement is also reflected as a significant
decrease in pain intensity alone. The decrease in pain in-
tensity does not continue beyond the end of treatment, as
although not significant, the mean pain intensity was
slightly larger at the first post-treatment visit than at the
end of treatment about 4 weeks earlier (Fig. 2). For pa-
tients whose initial therapy is unsuccessful, stepped-care
with a subsequent therapy is therefore necessary to attain
a further decrease in pain intensity and other signs and
symptoms beyond a critically low residual level.
Preference of Initial Therapy in Stepped-Care
Our suggestions for an optimal treatment strategy refer
to myogenous TMD which is not confounded by overt
psychological problems, or severe sleep bruxism (SB) as
diagnosed instrumentally [40]. A multi-therapy modality
is more appropriate for patients with major psycho-
logical problems [20]. An occlusal appliance may still be
preferred for active SB [40], because, apart from redu-
cing SB, further extreme tooth wear is prevented.
In order to assess the outcome of stepped-care from
the present study, a single telephone survey was carried
out at the end of the project, 1–4 years following the
end of a trajectory of 1–2 therapies [21]. This survey,
using the anamnestic questionnaire with eight items
from the TDC-procedure (assessing pain intensity by a
0–10 point score), revealed that 93% of all patients had
no need for treatment anymore. This success rate for
stepped-care corresponds with the mean of the range of
overall success rates (91–95%) in the stepped-care model
using the basic success rates of physiotherapy and splint
therapy, and a value of the modulation factor m which is
larger than one (m= 1.5; Table 5). This finding suggests
that, regardless of the sequence of physiotherapy and
splint therapy, the initial treatment triggers an improve-
ment that, although insufficient for patients whose initial
treatment becomes unsuccessful, enhances the success
rate of the subsequent treatment.
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Physiotherapy may be preferred as initial therapy over
occlusal splint therapy in stepped-care of myogenous
TMD, for four reasons. First, with a similar success rate
and effectiveness, the duration of physiotherapy is, on
average, 10.4 weeks shorter. Hence, patients whose ini-
tial physiotherapy is unsuccessful can continue earlier
with subsequent treatment thus lowering the risk on a
sustained chronicity of pain.
Second, the stepped-care model shows that small
and even moderately large inter-therapy differences in
basic success rate are not important. The overall suc-
cess rate of stepped-care does not depend on the
therapy sequence, irrespective of any inter-therapy
difference in basic success rate, if the success rate of
a subsequent therapy is not influenced by the preced-
ing one (m = 1). For a wide range of m-values around
m = 1 (0 < m < 2), the difference in overall success rate
between the two possible trajectories is smaller than
the inter-therapy difference in basic success rate.
Hence, the overall success rate of stepped-care hardly
depends on therapy sequence. For basic myogenous
TMD, an unsuccessful initial treatment most likely
enhances the success rate of the subsequent treatment
(m ≈ 1.5). The largest overall success rate of stepped-
care is then even attained by choosing the therapy
with the lower basic success rate as the initial ther-
apy, hence physiotherapy.
Third, the same therapeutic techniques of physiotherapy
can be applied to decrease pain or pain-related function
impairment of other body parts than facial ones, like the
neck and shoulders. Pain was not restricted to facial areas
in 69% of the patients (Table 1). A broader application of
physiotherapy might even increase its basic success rate.
Fourth, at least in the Netherlands, the costs of a trajec-
tory that starts with physiotherapy, are lower.
Physiotherapy might have a disadvantage, i.e. the number
of visits is on average 7.1 larger than for splint therapy. If
availability of a physiotherapist is limited, for example for
patients living in rural areas, or if patients have limitations
of transportation and/or time, splint therapy might still be
preferred as initial treatment. However, technology-assisted
interventions, including internet-based ones [41, 42], may
diminish the disadvantage of physiotherapy. In-person
treatment may, at least in part, be replaced by internet-
assisted treatment.
Limitations
This study includes some limitations. First, patients with
mainly basic signs and symptoms of solely myogenous
TMD were selected to facilitate straightforward conclusions
on therapy outcome. The prevalence of solely myogenous
TMD is low in samples of patients who are referred to a
specialized clinic, for example, 4.5% of all TMD patients in
a tertiary clinic [43], and 9.0% in the present study where
patients were mainly (85%) referred to a clinic for Special
Dental Care. However, this prevalence is much higher in a
more general clinic, i.e. 39.5% in an outpatient physical
therapy practice (myogenous TMD without arthralgia) [44],
and 47.8% in a university dental clinic [45]. The prevalence
is also higher, 36.1%, in a community sample of young
women (age 19–23 years) [46]. Hence, the results of the
present study are representative for about 40–48% of all
TMD patients, i.e. patients who have an age range of 18–65
years (median at about 32 years), and a need of treatment
for solely myogenous TMD. This conclusion is reinforced
by the finding that the patients from the present study are
largely comparable to those with myogenous TMD from
previous studies in which selection was less amended (for a
detailed discussion, see ref [23]).
Second, patient groups with placebo treatments or a
long waiting period were not included for ethical reasons.
Using a placebo group in non-pharmacological studies
may be theoretically, methodologically, practically, and
ethically unsound [47]. Regarding a placebo effect of oc-
clusal splint therapy, the effectiveness of a splint which
does not cover the teeth but only the palate (palatal splint)
is either similar [12], or corresponds in part to the effect-
iveness of an occlusal splint [15, 33]. However, occlusal
splint therapy and physiotherapy have in common an ex-
tensive non-noxious mechanical stimulation of peri-oral
and/or intra-oral tissues. A palatal splint also causes
mechanical stimulation of intra-oral tissues. Non-noxious
mechanical stimulation, hence stimulation of afferent A-β
fibres, may relieve pain by modulation of central pain
mechanisms [48, 49]. In order to avoid any stimulation of
tissues, a sham laser treatment may be an appropriate pla-
cebo treatment. Recording the patients’ expectation on
improvement will then be useful for assessing the role of
this factor in effectiveness of various treatment modalities.
Recording this expectation will also solve the third limita-
tion of the present study.
Although a non-treatment group was not included in
the present study, two waiting periods of about 4 weeks
were present in both treatment modalities, before and
after treatment. These waiting periods were long enough
to show, in addition with a 2-week-pain diary, that the
effect of one-time counselling at the initial visit (all pa-
tients) stabilized as well as the effect of an unsuccessful
treatment. An initial treatment was stepped up for
ethical reasons, when it was unsuccessful at a post-
treatment occasion of evaluation. Because the decrease
of pain intensity was halted following the end of an un-
successful initial treatment, it is unlikely that the success
rate and the last TDC-value would have altered by a
spontaneous improvement if a follow-up of 1 year were
completed. In a study using a waiting list of 1 year [34],
intensity of various types of pain did not change in myo-
genous TMD patients.
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Bias by regression to the mean is avoided by using
TDC-values as outcome parameter [19]. TDC is there-
fore useful in future research to examine changes of all
pronounced signs and symptoms during all phases, thus
from the initial visit up to the end of a possible second
treatment of a trajectory.
Conclusions
Physiotherapy and occlusal splint therapy have similar
success rates and effectiveness. Because the duration of
physiotherapy is on average 10.4 weeks shorter than that
of splint therapy, physiotherapy may be preferred as initial
therapy over occlusal splint therapy in stepped-care of
basic myogenous TMD which is not confounded by major
psychological problems or severe active sleep bruxism. Pa-
tients whose initial physiotherapy is unsuccessful can then
continue earlier with subsequent treatment. The stepped-
care model reinforces the conclusion on therapy prefer-
ence as the overall success rate of stepped-care in which
possibly two successive therapies are involved, hardly
depends on therapy sequence.
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